INNOVATE grants interim CEO options on 100,000 shares
Rhea-AI Filing Summary
INNOVATE Corp. (VATE) reported that Interim CEO Paul Voigt received a grant of stock options on September 15, 2026 to acquire 100,000 shares of common stock at an exercise price of $7.17 per share, with an exercise date of September 15, 2027 and expiration on September 17, 2036. The filing also lists three existing direct stock option positions, each covering 100,000 underlying shares with exercise prices of $5.67, $4.22, and $25.00 per share, expiring in 2035, 2034, and 2033, respectively. A footnote states the new option’s exercise price equals 110% of the 10-day VWAP on the grant date, and no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 100,000 shares
Grant/Award
4 txns
Insider
Voigt Paul
Role
Interim CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Opion (right to buy) F1 | 100,000 | $0.00 | $0.00 |
| holding | Stock option (Right To Buy) | -- | -- | -- |
| holding | Stock option (Right To Buy) | -- | -- | -- |
| holding | Stock option (Right To Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Opion (right to buy) — 100,000 contracts (Direct);
Stock option (Right To Buy) — 300,000 contracts (Direct)
Footnotes (1)
- F1. The option award was granted on September 15, 2026 with an exercise price set at 110% of the 10-day VWAP on the date of grant.
Key Figures
New options granted: 100,000 options
Exercise price (new grant): $7.17 per share
Exercise date (new grant): September 15, 2027
+5 more
8 metrics
New options granted
100,000 options
Grant to Interim CEO Paul Voigt on September 15, 2026
Exercise price (new grant)
$7.17 per share
Stock option grant covering 100,000 underlying shares
Exercise date (new grant)
September 15, 2027
Exercise date for new stock option award
Expiration date (new grant)
September 17, 2036
Expiration for new 100,000-share option award
Existing option exercise price
$5.67 per share
Direct stock option position expiring September 15, 2035 on 100,000 underlying shares
Existing option exercise price
$4.22 per share
Direct stock option position expiring September 15, 2034 on 100,000 underlying shares
Existing option exercise price
$25.00 per share
Direct stock option position expiring September 15, 2033 on 100,000 underlying shares
Total underlying shares in options reported
400,000 shares
One new and three existing stock option positions for Paul Voigt
Key Terms
Stock option (Right To Buy), 10-day VWAP, exercise price, Rule 10b5-1 trading plan
4 terms
Stock option (Right To Buy) financial
"The filing also lists three existing direct stock option (Right To Buy) positions"
10-day VWAP financial
"exercise price set at 110% of the 10-day VWAP on the date of grant"
10-day VWAP is the average price at which a stock traded over the past ten trading days, weighted by the number of shares exchanged at each price so bigger trades count more. Investors use it like a benchmark or reference line—similar to checking the average speed on a ten-day trip weighted by how long you traveled at each speed—to judge whether current prices are fair, to time trades, and to spot short-term trends or unusual activity.
exercise price financial
"with an exercise price of $7.17 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Rule 10b5-1 trading plan regulatory
"no Rule 10b5-1 trading plan is reported"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did INNOVATE Corp. (VATE) report for Interim CEO Paul Voigt in this Form 4?
The Form 4 reports that Interim CEO Paul Voigt received a grant of stock options for 100,000 shares of INNOVATE Corp. common stock on September 15, 2026, along with disclosure of three previously existing stock option positions.
What are the key terms of Paul Voigt’s new stock option grant at VATE?
The new stock option grant covers 100,000 underlying shares at an exercise price of $7.17 per share, with an exercise date of September 15, 2027 and an expiration date of September 17, 2036. The exercise price was set at 110% of the 10-day VWAP on the grant date.
What existing stock option awards for Paul Voigt are disclosed in this VATE filing?
Three existing direct stock option positions are listed, each tied to 100,000 underlying shares of common stock with exercise prices of $5.67, $4.22, and $25.00 per share, expiring in 2035, 2034, and 2033, respectively.
Was Paul Voigt’s new VATE option grant made under a Rule 10b5-1 plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as being under a plan, and the footnotes do not state that the transactions were made under any Rule 10b5-1 trading plan.
What pricing methodology was used for Paul Voigt’s new VATE option grant?
A footnote explains that the new stock option award’s exercise price was set at 110% of the 10-day VWAP on the September 15, 2026 grant date, linking the option strike price to the recent volume-weighted average market price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
